A：Gilead's key achievements in the second quarter included commercial excellence with year-over-year sales growth across therapeutic areas, positive clinical execution, and the FDA decision expected later this month on the once-daily oral treatment combining BTV rilagu and leno-capavibale.

A：Gilead's oncology business saw sales of Trodelvy up 20% year-over-year, reflecting strong demand across both triple-negative and pretreated HER2-negative metastatic breast cancer. Additionally, Trodelvy secured new approvals in the first line treatment of metastatic triple-negative breast cancer across PDL-1 status.

A：Gilead's liver disease business experienced significant growth with sales of Lodesivir more than doubling year-over-year. The drug continues to gain momentum as the leading second-line treatment for primary biliary cholangitis (PBC). Positive phase II data further support the opportunity for Lodesivir to reach more patients with PBC. Hepcidox was also launched in the U.S. this quarter as the first and only FDA-approved treatment for chronic hepatitis Delta virus (HCV).

A：Gilead's total product sales, excluding De, were $7.6 billion for the second quarter, marking a 10% year-over-year increase. Sequentially base business sales were up 12%, driven by strength across each of Gilead's therapeutic areas.

A：Gilead has updated its full-year HIV sales growth expectations to a range of 9% to 10% compared to the prior year, up from the previous guidance of 8% growth. This is attributed to continued strong growth in Viterbi, TAF, and Dolutegravir, as well as higher average realized prices and increased demand.

A：Viscose is expected to drive robust full-year growth due to pricing favorability and demand growth, with an expanding US prep market. The total prep business is operating at an annual run rate of $4 billion, and the company has a diverse pipeline of new prevention options in development.

A：The new positive results from the phase Iii ideal study are expected to enable potential expansion of lidell Z's leadership in the second line PBC population as early as next year.

A：Recent FDA approvals for tridadi in first line metastatic TNBC, across PDL one status, nearly double the addressable population and extend the opportunity to benefit patients following NCCN guideline updates. This is expected to further cement tri-delta as the backbone of treatment in metastatic TNBC.

A：The company has begun extensive launch readiness activities including optimizing sales, medical, and access teams, conducting pre-activation work, initiating contractual reviews, quality training, and engaging with payers to ensure broad and timely access. They are confident in the needle cell's profile and are encouraged by the strong interest received ahead of the potential launch.

A：The HIV pipeline is expanding with the addition of new daily and longer-acting orals and injectables for people with HIV. The company is evaluating potential new additions to their treatment portfolio, such as once daily Vitagraph plus lenacapavir or Vile for virally suppressed people with HIV, and is making progress on a novel oral regimen for the switch population. They are also advancing a twice-yearly treatment regimen using lenacapavir with investigational wholly owned long-acting Integra inhibitors.

A：The FDA has accepted the filing for once-weekly oral and acapela for HIV prevention, which is supported by the robust clinical profile of the drug from pivotal phase three trials. It is anticipated that the FDA will consider adding the first long-acting oral prevention option to Gilead's industry-leading portfolio.

A：The FDA's accelerated approval of helu deck, the first and only FDA approved treatment for chronic hepatitis Delta virus infection, is significant because chronic hepatitis Delta is considered the most severe form of viral hepatitis with rapid disease progression towards liver failure and death. Helu deck has been available in the EU since July.

A：The positive results from the Phase II ideal study evaluating delsey in patients with primary biliary cholangitis (PBC) showed statistically significant composite alkaline phosphatase normalization in patients whose disease remains inadequately controlled with alkaline phosphatase levels between 3 and 11 x the upper limit of normal.

A：Gilead has made several developments in oncology research, including closing the acquisition of Tubulus and its next-generation ADC platform, alongside the continued development of the Edo binder platform for future cell therapy. The acquisition of Tubulus and the presentation of updated safety and efficacy data from the Phase 1 study on GS 8824 in platinum-resistant ovarian cancer were key developments.

A：Gilead has made progress in developing GS 8824, a directed ADC, which demonstrated deep and durable responses in a platinum-resistant ovarian cancer study. The company has initiated a phase III clinical program in platinum-resistant ovarian cancer and is planning to enter further registrational development. Gilead's pipeline also includes a phase I clinical program in platinum-sensitive ovarian cancer and other advanced tumor types, and they continue to evaluate other potential research-stage candidates utilizing their Culet platform technologies.

A：With full control of Alito sales development, Gilead aims to maximize the long-term potential of allogeneic cell therapy, including in the treatment of multiple myeloma. The company is focusing on further developing the Ddom binder platform with deep and durable efficacy and a differentiated safety profile. Gilead has completed enrollment in the phase II imagine II study in second-line multiple myeloma and plans to potentially file for regulatory approval as early as 2023.

A：The Kite team's in vivo platform is designed to address class challenges of durability, safety, and manufacturing feasibility, and to provide scalability for broad expansion across oncology and autoimmune diseases. This platform enables multiple antigen targeting and utilizes a modular interior that allows for the optimization of car constructs and vector targets by disease, facilitating rapid development and improved operational efficiency.

A：The key factors contributing to Gilead's quarterly results include the strength and durability of Gilead's portfolio, disciplined operational execution, growth across HIV products, and the continued success of trodelvy and ladal. Sales were up year over year, and sequentially, they were driven by various factors, with the base business growing and other revenue contributing to the overall financial performance.

A：The non GAAP results for the second quarter include product gross margin, which was ed year over year and in line with the year's performance. There was an activity related to higher expenses, primarily reflecting the acquisitions of the recently acquired IPR and D. The non GAAP operating margin was negative ions, which is consistent with the strong margins delivered in prior quarters, and it remained in the top quartile of the peer group.

A：The non GAAP diluted EPS for the second quarter was negative 6 dollars 75 cents. This was influenced by higher revenue and adjusted for the acquisitions of arceli, butus, and oral medicines. Excluding these acquisitions, non GAAP diluted EPS would have been $200 script cents.

A：Gilead's business model has demonstrated leverage as the illustrative EPS has grown approximately ed compared to the same period last year, which is a favorable comparison to the total product sales growth of ed in the second quarter and ed in the first half of the year.

A：The full year sales and EPS guidance updates indicate that Gilead now expects base business sales to grow approximately script to script year over year, with a range between 29.8 and $30.1 billion. The company has also adjusted its expectations for total product sales to be in the range of ed ed and $30.4 billion. Furthermore, the updated guidance includes a lower end of the range for acquired IPRD expenses and an expectation of increased expenses for R&D and SG&A.

A：Gilead's near-term priorities include integrating the new programs and platforms into their business. They do not currently anticipate pursuing additional sizable M&A transactions for the remainder of the year but will remain opportunistic and continue to assess strategic opportunities to enhance their portfolio and create value.

A：There is an 85% of the total market that is still available for a weekly oral PrEP medication, which represents a significant opportunity for market expansion.

A：The company is working on compliance initiatives such as using electronic health records (EHR) and medical reminders to ensure PrEP persistency. They've also launched a support program called 'Ready to Go' that includes SMS reminders, educational resources, patient support links, and a nurse call center.

A：'Ready to Go' is designed to help PrEP individuals start and stay on the medication for the long term by providing SMS reminders, educational resources, links to patient support, friendly nudges, and access to a nurse call center.

A：Ongoing strategies include promoting awareness about HIV prep and the benefits of long-term use of PrEP. Upcoming strategies involve diversifying the HIV business across various treatment options, acquiring companies like Tubul, and providing more information about the pipeline.

A：Yes, Gilead continues to prioritize diversification of its core therapeutic areas, having worked on this in different ways over time. This includes the ongoing development of new options within HIV treatment and PrEP, as well as exploring acquisitions and expanding into oncology.

A：The company is awaiting approval for a new daily oral PrEP option by the end of the month, which is expected to be a significant step in diversifying the HIV treatment portfolio.

A：Gilead has seen recent growth in the oncology drug trabec, with a year-over-year increase of 20% and is approaching a $2 billion run rate. There is also excitement for the launch of new drugs like Breyanzi, and the company anticipates sharing more information on these areas later in the year.

A：The elimination of tax subsidies led to a situation where some patients became uninsured, impacting their ability to purchase insurance plans, and consequently affecting the treatment market. This had a softening effect on Q2 sales, with a year-on-year growth of 7% and quarter-over-quarter growth halting. However, it is expected that this impact will reverse and return to the 2 to 3% growth range.

A：The anticipated impact of the loss of insurance coverage on the treatment market is expected to be a transition of patients, resulting in a softer Q2. However, it is believed that this impact will reverse and that the market will return to the 2 to 3% growth trend previously observed.

A：The potential of GS-8008242 in non-squamous cell lung cancer is considered particularly interesting because it is expressed in non-squamous cell lung cancer and early data from trials are quite encouraging. The efficacy and tolerability observed in the trials suggest there is an opportunity for GS-8008242 to be a top-line treatment in non-small cell lung cancer, although it is considered still in early days and more data is needed.

A：The planned update for the alpha for beta 7 program will be shared at the Medics conference later in the year. The update will include phase 2 trial data with an emphasis on clinical remission and dysplasia remission, as well as an IBD endpoint. The program is a validated targeted approach, and the data is expected to demonstrate the potential of the treatment.

A：The introduction of Len and Vir should shape expectations for the HIV treatment market by expanding or switching leadership in the space. With the anticipated launch of Len in 2027, there is a positive physician response for the once-weekly oral option. The partnership with Merck, along with the current leadership in the naive market, provides an opportunity to really expand market leadership in HIV treatment.

A：The expected cannibalization impact of weekly oral medications, specifically on existing treatments like Stribildi, is uncertain. While there has been no significant cannibalization so far, with the introduction of the weekly oral, it is anticipated that there could be a shift from existing injectable treatments to the new weekly oral options, especially among patients who have been on a different treatment and are comfortable with it.

A：The projected dosing interval for the phase 2 trial of 3242 is not clear from the provided text, as it was described as a 'pending' detail that required further data to confirm.

A：When considering switching to the new weekly oral treatments, several factors should be taken into account. These include the molecule, mechanism, and full phase 3 data, as well as potential pros and cons relative to available treatments and newer daily options. The new treatments combine Lannate with GS 1720 or GS 3242, which are integrase inhibitors, and could be preferred due to strong safety profiles and resistance barriers, as per the understanding of current HIV treatment guidelines.